BEAM Latest Headlines

Evercore ISI Keeps Their Buy Rating on Beam Therapeutics (BEAM)

at www.tipranks.com (Wed, 25-Feb 10:45 AM)

Clear Street Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)

at www.tipranks.com (Wed, 25-Feb 8:16 AM)

RBC Capital Sticks to Its Hold Rating for Beam Therapeutics (BEAM)

at www.tipranks.com (Wed, 25-Feb 7:28 AM)

Beam Therapeutics: Clinical Momentum, Platform Validation, and De-Risked Financing Support Buy Rating and $47 Target

at www.tipranks.com (Wed, 25-Feb 5:05 AM)

Beam Therapeutics Expands Genetic Disease Pipeline and Extends Cash Runway with New Strategic Initiatives

Market Chameleon (Tue, 24-Feb 8:43 AM)

Beam Therapeutics Extends Cash Runway to 2029 as FDA Clears Accelerated Path for Lead Gene-Editing Therapies

Market Chameleon (Mon, 12-Jan 11:15 AM)

BEAM Secures FDA Support and Extends Cash Runway to 2029: Key Milestones Elevate Genetic Medicine Ambitions

Market Chameleon (Mon, 12-Jan 7:54 AM)